The effect of MDM2 inhibitors, nutlin-3/RG7388/HDM201, in combination with trametinib, was investigated for BRAFV600E and p53WT melanoma cancer cell lines, A375 and WM35, using median-effect analysis [25]. This evidence concerns the gene MDM2 and melanoma.